News und Analysen
![VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
VALBIOTIS Announces the First Patient First Visit in the International Phase II/III REVERSE-IT Clinical Study on TOTUM-63 to Reduce Type 2 Diabetes Risk Factors
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 - ALVAL, PEA/SME eligible) a Research & Development company committed to scientific innovation for preventing and combating metabolic
![Waters Corporation Names Udit Batra President and Chief Executive Officer](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Waters Corporation Names Udit Batra President and Chief Executive Officer
Waters Corporation (NYSE:WAT) (“Waters” or the “Company”) today announced that Udit Batra, Ph.D. has been named the Company’s President and Chief Executive Officer, effective September 1, 2020. He
![Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Novocure Announces Clinical Trial Collaboration with MSD to Evaluate Tumor Treating Fields Together with KEYTRUDA® (pembrolizumab) in Non-Small Cell Lung Cancer
Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD (a tradename of Merck & Co., Inc.), through a subsidiary, to develop Tumor Treating
![MorphoSys: Milliardendeals?!](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
MorphoSys: Milliardendeals?!
Bereits gestern Abend, nachbörslich, veröffentlichte das deutsche Biotechnologieunternehmen MorphoSys (WKN: 663200) eine bedeutende Ad hoc-Meldung. Die Aktie reagiert entsprechend.
Demnach hat der
![Medtronic to Acquire Medicrea](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Medtronic to Acquire Medicrea
Medtronic plc (NYSE:MDT), a global leader in medical technology, and Medicrea (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best Market – MRNTF), a pioneer in the transformation of
![Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2020 financial results on Wednesday, August 5th, before the market opens. A conference call has been scheduled
![STAAR Surgical Company to Hold 2020 Annual Meeting of Shareholders in Virtual Format](/assets/news/news3-3816cd3656012f9a06bae00ff06108b383643da017a8247fff474f84ea8a7c5a.png)
STAAR Surgical Company to Hold 2020 Annual Meeting of Shareholders in Virtual Format
STAAR Surgical Company (NASDAQ: STAA) today announced that to support the health and well-being of its shareholders, employees, directors, and communities due to the public health threat of the
![IMV Updates Rapid Progress on COVID-19 Vaccine Program](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
IMV Updates Rapid Progress on COVID-19 Vaccine Program
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, provides further details
![Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Quidel to Hold Second Fiscal Quarter 2020 Financial Results Conference Call on July 30th, 2020
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report second fiscal quarter 2020
![Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Premier Inc. ProvideGx™ Program Partners with Fresenius Kabi to Secure the Supply of Sedation Drug Essential for COVID-19 Care
Premier Inc. (NASDAQ: PINC), through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® (propofol) injectable emulsion, USP to healthcare providers, helping to stabilize
![Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program
![Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly targets the brain to treat difficult-to-treat and
![Qiagen: Muss Thermo-Fisher jetzt nachbessern?](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Qiagen: Muss Thermo-Fisher jetzt nachbessern?
Größter Gewinner im MDAX ist heute die Aktie des deutsch-niederländischen Biotechausrüsters Qiagen (WKN: A2DKCH). Grund hierfür sind die bereits gestern Abend überraschend vorgelegten vorläufigen
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 8, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Hanger Announces Date of 2020 Second Quarter Earnings Release and Conference Call](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Hanger Announces Date of 2020 Second Quarter Earnings Release and Conference Call
Hanger, Inc. (NYSE: HNGR), a leading provider of orthotic and prosthetic patient care services and solutions, today announced it will report its financial results for the second quarter and six
![Simulations Plus Reports Third Quarter FY2020 Financial Results](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Simulations Plus Reports Third Quarter FY2020 Financial Results
Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today reported
![Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Pfizer Pledges $100 Million to New Industry Fund to Help Fight Growing Threat of Antimicrobial Resistance
Pfizer Inc. (NYSE: PFE) announced today it has pledged $100 million to the new Antimicrobial Resistance (AMR) Action Fund, which launched today, to help address the significant global public health
![MEDICREA Reports First Half 2020 Sales](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
MEDICREA Reports First Half 2020 Sales
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED ; OTCQX Best Market –MRNTF), pioneering the transformation of spinal surgery through Artificial Intelligence, predictive modeling
![Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
Transgene and Hypertrust Patient Data Care Announce Successful Go-Live of the World’s First Blockchain Solution for Clinical Trials of Personalized Healthcare
Regulatory News:
Transgene (Paris:TNG) and Hypertrust Patient Data Care today announced as a world premiere the first productive blockchain solution for clinical trials of personalized
![THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 AND IMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
THERANEXUS ANNOUNCES ITS CASH POSITION AS OF 30 JUNE 2020 AND IMPLEMENTATION OF A MANDATORY CONVERTIBLE BOND FACILITY
- Pro forma cash of €13.3 M at 30 June 2020
- Implementation of financing for a maximum total of €4.2 million over 12 months through the issuance of warrants to subscribe mandatory convertible bonds
![Chemed To Report Second-Quarter 2020 Earnings July 29, Related Conference Call To Be Held On July 30](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Chemed To Report Second-Quarter 2020 Earnings July 29, Related Conference Call To Be Held On July 30
Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the second quarter ended June 30, 2020, on Wednesday, July 29, 2020, following the close of trading on the
![EOS imaging Announces the First EOSedge™ Installation in Germany](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
EOS imaging Announces the First EOSedge™ Installation in Germany
Regulatory News:
EOS imaging (Euronext, FR0011191766 - EOSI - PEA-PME eligible), the leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical
![Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Illumina Launches TruSight Software Suite to Accelerate the Identification of Genetic Diseases
Illumina, Inc. (NASDAQ: ILMN) is bringing turn-key data analysis solutions to accelerate and facilitate the adoption of whole-genome sequencing with the launch of the TruSight™ Software Suite
![VALBIOTIS: Start der internationalen klinischen Studie Phase-II/III-REVERSE-IT zu TOTUM-63 zur Verringerung der Risikofaktoren für Typ-2-Diabetes genehmigt](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
VALBIOTIS: Start der internationalen klinischen Studie Phase-II/III-REVERSE-IT zu TOTUM-63 zur Verringerung der Risikofaktoren für Typ-2-Diabetes genehmigt
VALBIOTIS (FR0013254851 - ALVAL / PEA/SME-qualifiziert), ein Forschungs- und Entwicklungsunternehmen mit Schwerpunkt auf wissenschaftlicher Innovation zur Vorbeugung und Bekämpfung von
![Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, and Atreca, Inc. (Atreca)